tldrdailynews.com logo
Tag

Cancer Vaccine

All articles tagged with #cancer vaccine

AI helps tailor cancer vaccine for dog, but scientists urge caution
science-tech21 days ago

AI helps tailor cancer vaccine for dog, but scientists urge caution

An Australian tech entrepreneur used AI tools to help design a personalized mRNA cancer vaccine for his eight-year-old dog, Rosie, after mast cell tumors persisted post-surgery and chemotherapy. DNA sequencing of Rosie’s tumor identified mutations (neoantigens); AI helped select targets, and researchers at the University of New South Wales turned these into an experimental vaccine administered to Rosie, with several tumors shrinking and the dog showing improved energy. However, this is a single case, not a controlled study, so it cannot be taken as a cure and highlights the need for robust testing, ethical safeguards, and careful interpretation of AI-assisted results before broader use.

via The Conversation|
#ai#cancer-vaccine#dna-sequencing
CD27 boost could unlock long-lasting cancer vaccine immunity
health-and-medicine2 months ago

CD27 boost could unlock long-lasting cancer vaccine immunity

A 20-year-old breast cancer vaccine trial shows all participants are still alive decades later, suggesting durable immune memory. Researchers found persistent CD27-marked CD4+ T cells can recognize the cancer, hinting that CD27 could make cancer vaccines more effective. In mice, combining the vaccine with a CD27-activating antibody nearly doubled tumor elimination (about 40% complete responses vs 6% with vaccine alone); adding extra support for CD8+ T cells pushed tumor rejection to ~90%. These findings imply CD27 could be a key addition to cancer vaccines and compatible with existing therapies.

via ScienceDaily|
#cancer-vaccine#cd27#cd4-t-cells
Decades-Old Breast Cancer Vaccine Triggers Durable Immune Memory, New Boosting Approach Emerges
science2 months ago

Decades-Old Breast Cancer Vaccine Triggers Durable Immune Memory, New Boosting Approach Emerges

Researchers studied survivors from a decades-old breast cancer vaccine trial and found they retain powerful CD27+ immune memory years later. In mice, combining a CD27-activating antibody with a HER2-targeting vaccine dramatically increased tumor rejection, largely via CD4+ T cells and, with additional CD8+ T-cell support, boosted efficacy to near 90%. The findings suggest CD4+ T cells can drive lasting anti-tumor immunity and that a single CD27 boost alongside vaccines could enhance cancer immunotherapies in humans.

via SciTechDaily|
#cancer-vaccine#cd27#cd4-t-cells
Personalized Melanoma Vaccine Shows Strong, Lasting Benefit with Immunotherapy
health2 months ago

Personalized Melanoma Vaccine Shows Strong, Lasting Benefit with Immunotherapy

Moderna and Merck report promising results for a patient-tailored mRNA cancer vaccine paired with Keytruda in high-risk melanoma. The vaccine, designed from a patient’s tumor mutations (neoantigens), reduced recurrence or death by 49% versus immunotherapy alone and demonstrated durable immune memory over five years, signaling a potential breakthrough for personalized cancer vaccines and future skin-cancer prevention.

via ZME Science|
#cancer-vaccine#health#immunotherapy
Moderna Surges 10% on Positive Melanoma Trial Results for Cancer Vaccine
markets2 months ago

Moderna Surges 10% on Positive Melanoma Trial Results for Cancer Vaccine

Moderna shares rose about 10% after Phase 2 data showed its cancer vaccine, when combined with Keytruda, reduced relapse or death risk in melanoma, signaling potential for its oncology pipeline as Covid-era vaccine sales fade and cash stockpiles dwindle. Evercore ISI called the asset a key value driver, while the stock remains rated a Hold by analysts with notable downside risk baked into targets.

via TipRanks|
#cancer-vaccine#keytruda#markets
Personalized mRNA melanoma vaccine trims five-year recurrence risk by almost 50%, Moderna and Merck report
health2 months ago

Personalized mRNA melanoma vaccine trims five-year recurrence risk by almost 50%, Moderna and Merck report

In a Phase 2 trial of 157 high‑risk stage 3/4 melanoma patients, Moderna and Merck’s personalized mRNA vaccine (mRNA-4157) plus Keytruda reduced recurrence or death at five years by about 49% versus Keytruda alone. Earlier two- and three-year data showed similar risk reductions (44% and 49%). Safety was similar between groups, with fatigue, injection-site pain, and chills most common. Full data aren’t yet published; a Phase 3 trial is underway and more data from this program are expected.

via Ars Technica|
#cancer-vaccine#health#immunotherapy
Preventive Cancer Vaccine Sparks Hope for Lynch Syndrome Carriers in Early Trial
health2 months ago

Preventive Cancer Vaccine Sparks Hope for Lynch Syndrome Carriers in Early Trial

A phase 1b/2 trial of a preventive cancer vaccine for Lynch syndrome carriers, including Kevin Heyink, showed the vaccine is safe and elicits a lasting immune response. In a 45-participant trial, vaccinated individuals had fewer precancerous lesions and no advanced tumors; Heyink has since had three cancer-free colonoscopies in a row. The vaccine uses a modified adenovirus to train the immune system to recognize Lynch-related proteins, offering hopeful potential to reduce cancer risk, though larger trials are needed before wider use.

via TODAY.com|
#cancer-vaccine#clinical-trial#health